dc.date.accessioned | 2024-02-10T18:28:41Z | |
dc.date.available | 2024-02-10T18:28:41Z | |
dc.date.created | 2023-09-27T15:23:47Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Federico, Lorenzo Tvedt, Tor Henrik Anderson Gainullin, Murat Osen, Julie Røkke Chaban, Viktoriia Lund, Kathrine Persgård Tietze, Lisa Tran, Trung Lund-Johansen, Fridtjof Kared, Hassen Lind, Andreas Vaage, John T. Stratford, Richard Tennøe, Simen Malone, Brandon Clancy, Trevor Myhre, Anders Eivind Gedde-Dahl, Tobias Munthe, Ludvig Andre . Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study. Frontiers in Immunology. 2023, 14:1210899, 1-13 | |
dc.identifier.uri | http://hdl.handle.net/10852/107849 | |
dc.description.abstract | Poor overall survival of hematopoietic stem cell transplantation (HSCT) recipients who developed COVID-19 underlies the importance of SARS-CoV-2 vaccination. Previous studies of vaccine efficacy have reported weak humoral responses but conflicting results on T cell immunity. Here, we have examined the relationship between humoral and T cell response in 48 HSCT recipients who received two doses of Moderna’s mRNA-1273 or Pfizer/BioNTech’s BNT162b2 vaccines. Nearly all HSCT patients had robust T cell immunity regardless of protective humoral responses, with 18/48 (37%, IQR 8.679-5601 BAU/mL) displaying protective IgG anti-receptor binding domain (RBD) levels (>2000 BAU/mL). Flow cytometry analysis of activation induced markers (AIMs) revealed that 90% and 74% of HSCT patients showed reactivity towards immunodominant spike peptides in CD8 + and CD4 + T cells, respectively. The response rate increased to 90% for CD4 + T cells as well when we challenged the cells with a complete set of overlapping peptides spanning the entire spike protein. T cell response was detectable as early as 3 months after transplant, but only CD4 + T cell reactivity correlated with IgG anti-RBD level and time after transplantation. Boosting increased seroconversion rate, while only one patient developed COVID-19 requiring hospitalization. Our data suggest that HSCT recipients with poor serological responses were protected from severe COVID-19 by vaccine-induced T cell responses. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study | |
dc.title.alternative | ENEngelskEnglishRobust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study | |
dc.type | Journal article | |
dc.creator.author | Federico, Lorenzo | |
dc.creator.author | Tvedt, Tor Henrik Anderson | |
dc.creator.author | Gainullin, Murat | |
dc.creator.author | Osen, Julie Røkke | |
dc.creator.author | Chaban, Viktoriia | |
dc.creator.author | Lund, Kathrine Persgård | |
dc.creator.author | Tietze, Lisa | |
dc.creator.author | Tran, Trung | |
dc.creator.author | Lund-Johansen, Fridtjof | |
dc.creator.author | Kared, Hassen | |
dc.creator.author | Lind, Andreas | |
dc.creator.author | Vaage, John T. | |
dc.creator.author | Stratford, Richard | |
dc.creator.author | Tennøe, Simen | |
dc.creator.author | Malone, Brandon | |
dc.creator.author | Clancy, Trevor | |
dc.creator.author | Myhre, Anders Eivind | |
dc.creator.author | Gedde-Dahl, Tobias | |
dc.creator.author | Munthe, Ludvig Andre | |
cristin.unitcode | 185,53,18,75 | |
cristin.unitname | K.G. Jebsen senter for B-cellekreft - del UiO | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2179543 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Immunology&rft.volume=14:1210899&rft.spage=1&rft.date=2023 | |
dc.identifier.jtitle | Frontiers in Immunology | |
dc.identifier.volume | 14 | |
dc.identifier.doi | https://doi.org/10.3389/fimmu.2023.1210899 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1664-3224 | |
dc.type.version | PublishedVersion | |
cristin.articleid | 121899 | |
dc.relation.project | NFR/? | |